Currently this content is only available in German.
Dieser Inhalt ist momentan nur auf Deutsch verfügbar.

0900 712 712
(3.23 CHF / min. from the Swiss landline, possibly additionally 8 Rp. / min. in the waiting loop by network operator)
0900 712 713

(3.12 CHF / min. for calls from prepaid cell phones, possibly additionally 8 Rp. / min. in the waiting loop by network operator)

Notfallnummern

Anmeldung

Sie haben bereits ein Konto?

 

Sie sind noch nicht registriert?

Emergency Contact 24h

0900 712 712

(3.23 CHF / min. from the Swiss landline, possibly additionally 8 Rp. / min. by network operator)

 
 

0900 712 713

(3.12 CHF / min. for calls from prepaid cell phones, possibly additionally 8 Rp. / min. by network operator)


Important Numbers

  • 144   Ambulance
  • 145   Tox Center (Poisoning)
  • 117   Police
  • 118   Fire Department

Kontakt Box

UKBB

University Children’s Hospital Basel
Spitalstrasse 33
4056 Basel
Switzerland

T +41 61 704 12 12
F +41 61 704 12 13

Contact

Appointment cancellation
Collection / Reminder 
Patient invoice
Please contact me
Other
empty
Appointment cancellation

For making an appointment or the postponement of an appointment, please contact polyclinic head office +41 61 704 12 20

 
Collection / Reminder 

Collection / Reminder

 
Patient invoice

Patient invoice

 
Please contact me

Please contact me

 
 

How would you like to be contacted?

 
Other

Other

 
empty
 
 
 

Neuromuscular Research

One of our main research interests is to identify objective clinical endpoints or surrogate imaging markers that are useful in evaluating disease progression in muscular dystrophies and related neuromuscular disorders. In close collaboration with the Department of Radiological Physics of the University Basel (Prof. Oliver Bieri) we are developing and evaluating novel quantitative MRI sequences to distinguish healthy from fatty degenerated muscle tissue. These methods are clearly superior to clinical scores when assessing the effect of novel interventions and treatments on disease progression.

Our second area of scientific interest includes clinical studies aimed to improve the energetic situation of muscle cells in patients with neuromuscular diseases. A positive effect on muscle metabolism of a treatment with metformin and L-arginine was assessed in a pilot study on 5 patients with Duchenne muscular dystrophy. Larger placebo controlled clinical trials using the same hypothesis of an amelioration of muscle metabolism were conducted on patients with Duchenne muscular dystrophy and Becker muscular dystrophy and were funded by Swiss National Science Foundation.

Research Projects

Treatment with L-citrulline in patients with post-polio syndrome – a randomized double blind placebo controlled study

Post-polio syndrome (PPS) is a condition that affects many polio patients years after recovery from an initial acute attack of the poliomyelitis virus. Most often patients start to experience slowly progressive muscle weakness and fatigue. We perform a randomised, placebo controlled trial to assess the influence of an oral treatment with L-citrulline on energy metabolism in muscles of post-polio patients and its effect on muscle function, endurance and quality of life. This study is sponsored by the Thomi-Hopf-Foundation.

ClinicalTrials.gov Identifier: NCT02801071

Recruitment of patients has been terminated.

Ultrasonographic reference values for peripheral nerves and nerve roots in the normal population of children and adolescents

The examination of the peripheral nervous system with ultrasonogaphy is an emerging non-invasive technique that became popular in the last few years. To distinguish a pathological swelling of the nerves from normal aspects a comparison with normal values from a group of healthy children is important. This investigator-initiated study aims to establish normal values for cross sectional areas of several upper and lower limb nerves and cervical roots in children and adolescents from 2 to 18 years.

ClinicalTrials.gov Identifier:NCT02570802

We are actually recruiting patients, please contact us.

Phase III study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrohy using Glucocorticoids

At the university’s children hospital (UKBB), the phase III, double-blind, randomized, placebo-controlled trial SIDEROS (sponsored by Santhera®) aims to assess the efficacy of Raxone in slowing the rate of respiratory function decline in Duchenne muscular dystrophy (DMD) patients receiving concomitant glucocorticoids. Study participants will receive either Raxone (900 mg/day; given as 2 tablets 3 times a day with meals) or placebo for 78 weeks (18 months). The primary endpoint of the trial is change from baseline to week 78 in forced vital capacity % predicted (FVC%p). Patients completing the trial will be offered the opportunity to enroll in an open label extension study where all patients receive Raxone.

ClinicalTrials.gov Identifier:NCT02814019

We are recruiting patients, please contact us.

Treatment with Tamoxifen in Patients with Duchenne Muscular Dystrophy (TAM-DMD) – a randomized double blind placebo controlled multicenter study

In this study the effect of Tamoxifen is evaluated in boys with Duchenne muscular dystrophy. Using the mouse DMD model encouraging results have been shown concerning the muscle function during a treatment with tamoxifen. Patients will be recruited internationals in 9 centers (7 countries), the trial will be coordinated by the UKBB (sponsored by EU, SNF, patient organizations: Duchenne UK, NL and Monaco).

We are not yet recruiting patients. Please contact us for more information. 

Safety, tolerability and efficacy of exogenous ketone bodies in migraine prevention (MigraKet): A randomised, placebo-controlled, double-blind study

Approx. one billion people are suffering from migraine worldwide and yet, therapeutic options are still very limited. Research suggests that changes in energy metabolism could be part of migraine pathophysiology. Ketone bodies (KB) are endogenous alternative energy substrates. Our clinical trial assesses the efficacy and safety of KB supplements in 60-90 adult migraineurs (5-14 migraine days / months) at the University Hospital Basel. The total duration of the trial is approx. 6 months, consisting of 4 weeks baseline, 12 weeks intervention with KB powder or matched placebo and 8 weeks follow-up. The primary endpoint is the change in migraine days at the end of intervention compared to baseline. Additionally, changes in gene expression, fat-, protein- and glucose metabolism, inflammatory markers and quality of life will be examined.

We are currently recruiting. Please contact us for more information on the study


 

Group members

  • Andrea Klein, MD
  • Caroline Baya, Clinical Research Coordination
  • Cornelia Enzmann, MD
  • Vanya Gocheva, PhD student
  • Patricia Hafner, MD
  • Sara Nagy, MD
  • Anna-Lena Orsini, MD
  • Niveditha Putananickal, PhD student
  • Daniela Rubino, Head of Clinical Research Coordination and Project Management
  • Simone Schmidt, MD
  • Jonas Schroeder, MD student
  • Karin Wild, Clinical Research Coordination and Study Nurse
 

Emergencies

0900 712 712

(3.23 CHF/min. CH-landline, possibly additionally 8 Rp. / min. by network operator)

0900 712 713

(3.12 CHF/min. prepaid cell phones, possibly additionally 8 Rp. / min. by network operator)

Site Map

Contact

University Children’s Hospital Basel
Spitalstrasse 33
4056 Basel / Switzerland

T +41 61 704 12 12
F +41 61 704 12 13

 

Emergency

Contact

University Children’s Hospital Basel
Spitalstrasse 33
4056 Basel / Switzerland

T +41 61 704 12 12
F +41 61 704 12 13

© UKBB, 2018